Treating Caregivers Who Smoke at AFCH

March 27, 2026 updated by: University of Wisconsin, Madison

Treating Nicotine Addiction in Caregivers of Children at American Family Children's Hospital

The purpose of this research study is to 1) see if a smoking cessation program is something that caregivers will use while their child is hospitalized, 2) see if caregivers think this program is something we should institute across the hospital, and 3) see if this program can help caregivers reduce their smoking.

Participants will:

  • Complete a survey regarding smoking behavior and thoughts about quitting;
  • Undergo a 20-minute counseling session; and,
  • Use nicotine patches and mini-lozenges for 2 weeks

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

All participants will receive a one-time visit with the study physician. This visit will consist of a brief counseling session. Counseling sessions will last approximately 20 minutes and cover the 3 objectives of 1) review participants' motivation for smoking and for quitting; 2) use the information on participants' motives to provide tailored education regarding a) benefits of quitting smoking to the caregiver and the child, b) strategies to reduce nicotine withdrawal symptoms/urges to smoke during the hospitalization, and c) benefits of smoke-free home and car rules; and, 3) review smoking cessation resources.

After the counseling session, participants will be provided a 2-week supply of nicotine patches and nicotine mini-lozenges, along with instructions for their use. The study physician will review how to use the medication, dosing, benefits of use, and potential side effects of use.

Within 24 hours of discharge, participants will be contacted to complete a post-intervention survey, which will assess nicotine replacement therapy (NRT) use during the hospitalization and likelihood that the participant would recommend program implementation in the hospital. Smoking behavior during the child's hospitalization will be examined, including assessments of 1) number of cigarettes smoked per day and 2) number of times participant left the child's bedside to smoke per day. Participant's self-efficacy and interest in quitting smoking will be assessed, using the same questions from the pre-intervention survey, to assess for changes after the intervention.

Participants will be contacted 2 weeks after discharge with a link to complete the follow-up survey to again assess current smoking status, use of NRT post-hospitalization, self-efficacy and interest in quitting smoking, establishment of smoke-free home and car rules, and interest in ongoing smoking cessation treatment.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • American Family Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Hospitalized child will have a 'yes' response to the screening question, "Does anyone in your household smoke"
  • Hospitalized child is expected to be admitted for >24 hours
  • Caregiver is at least 18 years of age
  • Participant self-identifies as the primary caregiver of the hospitalized child during the hospitalization
  • Participant smokes ≥5 cigarettes per day
  • Participant is willing and able to use NRT
  • Participant is not currently pregnant, trying to get pregnant, or breastfeeding and willing to use acceptable birth control for duration of medication use
  • Participant is willing to comply with all study procedures and be available for the duration of the study

Exclusion Criteria:

  • Contraindication to NRT use (pregnancy, myocardial infarction in past 2 weeks)
  • Previous reaction to the nicotine patch or mini-lozenge that prevented them from continuing to use it
  • Current use of smoking cessation medications (any NRT, bupropion, varenicline)
  • Caregiver's child is being cared for by study physician (Dr. Brian Williams)
  • Need for an interpreter

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Caregivers of hospitalized children
Adults will receive a 2-week supply of nicotine patches to place on skin (14mg or 21mg; dosing depending on tobacco use per package insert) and oral nicotine mini-lozenges (2mg, 4mg, dosing depending on tobacco use per package insert). All participants will also receive a single smoking cessation counseling session with a physician. Surveys will be completed pre-intervention, within 24 hours of hospital discharge, and 2-weeks after hospital discharge.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Enrollment in Study
Time Frame: Study recruitment, approximately 6 months
Enrollment will be measured as a relation between the number of people invited to enroll versus the number who enroll
Study recruitment, approximately 6 months
NRT Use
Time Frame: 2 weeks post-discharge, up to 4 weeks
Number of participants who use the NRT provided
2 weeks post-discharge, up to 4 weeks
Acceptability of Smoking Intervention
Time Frame: 2 weeks post-discharge, up to 4 weeks
Self-report by participant via survey. Score ranges from 1-7, with 1 indicating would not recommend implementing cessation program and 7 indicating definitely recommend implementing program.
2 weeks post-discharge, up to 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Number of Cigarettes Smoked Per Day
Time Frame: Baseline to 2 weeks post-discharge, up to 4 weeks
Self-report by participants via survey
Baseline to 2 weeks post-discharge, up to 4 weeks
Change in Trips Outside
Time Frame: From admission to discharge, up to 4 weeks
Self-report by participant via survey
From admission to discharge, up to 4 weeks
Change in Self-confidence in Quitting Smoking
Time Frame: Baseline to 2 weeks post-discharge, up to 4 weeks
Self-report by participant via survey. Score ranges from 1-7, with 1 indicating no confidence in ability to quit smoking and 7 indicating extreme confidence.
Baseline to 2 weeks post-discharge, up to 4 weeks
Change in Motivation to Quit Smoking
Time Frame: Baseline to 2 weeks post-discharge, up to 4 weeks
Self-report by participant via survey. Score ranges from 1-7, with 1 indicating no motivation to quit smoking and 7 indicating extreme motivation.
Baseline to 2 weeks post-discharge, up to 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brian Williams, MD, University of Wisconsin, Madison

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 5, 2024

Primary Completion (Actual)

April 18, 2025

Study Completion (Actual)

April 18, 2025

Study Registration Dates

First Submitted

September 12, 2023

First Submitted That Met QC Criteria

September 19, 2023

First Posted (Actual)

September 25, 2023

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

March 27, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2023-0727
  • Protocol Version 5/23/23 (Other Identifier: UW Madison)
  • SMPH\PEDIATRICS\PED HOSP (Other Identifier: UW Madison)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Smoking

Clinical Trials on Nicotine Replacement Product

Subscribe